Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josephine A Mauskopf

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|April 12, 2006
Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic conceptsMohan V Bala, Josephine A Mauskopf
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Budget impact analysis: review of the state of the artJosephine A Mauskopf, Stephanie Earnshaw, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 6, 2009
Rate, type, and cost of pelvic organ prolapse surgery in Germany, France, and EnglandDhinagar Subramanian, Karine Szwarcensztein, Josephine A Mauskopf, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 18, 2017
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UKEvelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, et al.
Journal of Managed Care Pharmacy : JMCP|April 5, 2005
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settingsJosephine A Mauskopf, Clark Paramore, Won Chan Lee, et al.
Pharmacoeconomics|April 13, 2002
A Monte Carlo simulation for modelling outcomes of AIDS treatment regimensAnke Richter, Brett Hauber, Kit Simpson, et al.
Journal of Medical Economics|July 9, 2010
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidenceJosephine A Mauskopf, Christine L Baker, Brigitta U Monz, et al.
World Journal of Surgical Oncology|July 10, 2012
Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costsJosephine A Mauskopf, Sean D Candrilli, Hélène Chevrou-Séverac, et al.
Depression and Anxiety|October 4, 2008
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorderJosephine A Mauskopf, Gregory E Simon, Anupama Kalsekar, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|April 12, 2006
Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic conceptsMohan V Bala, Josephine A Mauskopf
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Budget impact analysis: review of the state of the artJosephine A Mauskopf, Stephanie Earnshaw, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 6, 2009
Rate, type, and cost of pelvic organ prolapse surgery in Germany, France, and EnglandDhinagar Subramanian, Karine Szwarcensztein, Josephine A Mauskopf, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 18, 2017
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UKEvelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, et al.
Journal of Managed Care Pharmacy : JMCP|April 5, 2005
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settingsJosephine A Mauskopf, Clark Paramore, Won Chan Lee, et al.
Pharmacoeconomics|April 13, 2002
A Monte Carlo simulation for modelling outcomes of AIDS treatment regimensAnke Richter, Brett Hauber, Kit Simpson, et al.
Journal of Medical Economics|July 9, 2010
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidenceJosephine A Mauskopf, Christine L Baker, Brigitta U Monz, et al.
World Journal of Surgical Oncology|July 10, 2012
Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costsJosephine A Mauskopf, Sean D Candrilli, Hélène Chevrou-Séverac, et al.
Depression and Anxiety|October 4, 2008
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorderJosephine A Mauskopf, Gregory E Simon, Anupama Kalsekar, et al.
Pageof 2